# Neuropathology Core

> **NIH NIH P30** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $287,987

## Abstract

ABSTRACT- NEUROPATHOLOGY CORE
The Neuropathology (NP) Core provides for diagnostic neuropathological evaluations of: 1) patients and control
subjects enrolled in the Clinical Core (CC), and 2) other clinically well documented patients with
neurodegenerative disease. The NP Core aims to enhance understanding of the heterogeneity of AD/ADRD
to develop better biomarkers and discover novel and effective therapeutic approaches that promote progress
towards achieving the NAPA research implementation milestones. The protocols used by the NP Core will
be state of the art and consistent with 21st century brain banking procedures. These will be essential to meet the
increasingly sophisticated needs of the AD research community. We will emphasize delineating the presence of
overlapping neurodegenerative syndromes. In this renewal, we will continue to emphasize the central theme of
the NYU ADRC: elucidating the clinico-pathological substrates that underlie the transitions between normal
aging, subjective cognitive decline (SCD), MCI, and dementia to help develop novel interventions that delay or
prevent these transitions. The overall objectives of the NP Core of the NYULH ADRC are to provide staff,
technical resources, laboratory facilities, and expertise to investigate the structural and molecular properties of
the brains of both patients with ADRC and those of normal controls. Aims 1–3 of the NP core encompass the
key neuropathology functions of the NP Core. Aims 4 and 5 will develop innovative neuropathological
technologies. The emerging clinical evaluation system of ATN—which is proposed to underlie transitional stages
between normal aging to SCD, SCD to MCI, and MCI to early dementia—needs to be correlated with
comprehensive neuropathological measures that also reflect disease heterogeneity. In addition, while brain
tissue is an essential resource, it cannot be developed into dynamic cellular models. Hence, the NP Core has
launched a new induced pluripotent stem cell (iPSC) program, providing investigators with an easily replenished
source of tissue to address key questions about the heterogeneous pathogenesis of AD/ADRC. Aims 6 and 7
focus on using NP Core resources to train the next generation of neuropathologists and translational
neuroscientists conducting research on AD/ADRD, support their studies to develop novel therapeutic targets,
and promote educational outreach about brain and biospecimen donation. The combination of these aims will
help the NP Core to develop better biomarkers and to discover novel effective, therapeutic approaches; hence,
accelerating progress towards achieving the NAPA research implementation milestones.

## Key facts

- **NIH application ID:** 10148611
- **Project number:** 5P30AG066512-02
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** THOMAS M WISNIEWSKI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $287,987
- **Award type:** 5
- **Project period:** 2020-05-01 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10148611

## Citation

> US National Institutes of Health, RePORTER application 10148611, Neuropathology Core (5P30AG066512-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10148611. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*